Table 2. Studies included and criteria to conclude lipofilling is safe.
| Study | Interval between resection and lipofilling | Time to follow-up after lipofilling | Comparison group | Subgroup analysis of ER/PR/HER-2 in cases of recurrence | Matched for ER/PR/Her2 | Adequate powering |
|---|---|---|---|---|---|---|
| Biasio et al. | Immediate | 36 months | Institutional database | Meets criteria | ** | Not quantified |
| Biazus et al. | Immediate | 40.8 months | Not quantified | |||
| Brenelli et al. | 76±30.9 months | 34.4±15.3 months | Meets criteria | Not quantified | ||
| Debald et al. | 71.6 months (7–291.3 months) | 23 days | Not quantified | |||
| Gale et al. | 54 months | 32 months | Matched controls | ER*** | Not quantified | |
| Garcia et al. | Immediate | 12 months | Not quantified | |||
| Kahn et al. | Immediate | 36 months | Institutional database | ** | Not quantified | |
| Krastev et al. | 51.6 months | 60 months | Matched controls | Meets criteria | **** | Not quantified |
| Mazur et al. | Minimum of 12 months | 36 months | Matched controls | Not quantified | ||
| Mestack et al. | 50 months | 27 months | Matched controls | ER and PR***** | Not quantified | |
| Perez-Cano et al. | Minimum of 12 months | 12 months | Not quantified | |||
| Petit, Botteri et al. | 56 months (8–155 months) | 26 months (1–128 months) | Matched controls | ER****** | Not quantified | |
| Petit, Lohsiriwat et al. | 39.7 months (0–216 months)* | 19.2 months | Not quantified | |||
| Petit, Rietjens et al. | 32% <1 year | 38 months lipofilling | Matched controls | Meets criteria | ER and PR****** | Not quantified |
| 22% 1–2 years | 42 months control | |||||
| 10% 2–3 years | ||||||
| 36% >3 years | ||||||
| Rietjens et al. | 35.2 months | 6 months | Not quantified | |||
| Silva et al. | 36 months (4–324 months) | 31 months | Meets criteria | Not quantified | ||
| Silva et al. | 48.3 (0–269 months) | 40.4 months | Matched controls | Meets criteria | ER*** | Not quantified |
| Sorrentino et al. | 24.2% <1 year | 51.2 (±35 months) | Matched controls | Meets criteria | Luminal A | Not quantified |
| 45.1% 1–2 years | Luminal B | |||||
| 30.7% >3 years | Triple negative | |||||
| Stumpf et al. | Immediate | 34 months | Institutional database | Meets criteria | ** | Not quantified |
*, did not distinguish interval for BCS group, study included both mastectomy and BCS; **, unmatched control, comparison group of BCS performed during the same time period at the same institution without comment on ER/PR/HER-2; ***, statistically significant difference in Her-2+ status between fat grafting and control groups without stratifying for type of surgery (BCS vs. mastectomy), PR and triple negative unmatched but equally represented without stratifying for type of surgery; ****, unmatched but equal representation of ER/PR/Her2 positive and Triple Negative disease in study arms in all surgical groups without stratifying for type of surgery; *****, no comment on HER-2 status or triple negative distribution between groups; ******, unmatched but equal representation of Her-2 and PR in study arms in all surgical groups without stratifying for type of surgery, no comment on representation of triple negative disease. BCS, breast conservation surgery.